1-Deoxynojirimycin: Occurrence, Extraction, Chemistry, Oral Pharmacokinetics, Biological Activities and in Silico Target Fishing

Total Page:16

File Type:pdf, Size:1020Kb

1-Deoxynojirimycin: Occurrence, Extraction, Chemistry, Oral Pharmacokinetics, Biological Activities and in Silico Target Fishing molecules Review 1-Deoxynojirimycin: Occurrence, Extraction, Chemistry, Oral Pharmacokinetics, Biological Activities and In Silico Target Fishing Kuo Gao 1,†, Chenglong Zheng 1,2,†, Tong Wang 2, Huihui Zhao 1, Juan Wang 1, Zhiyong Wang 1, Xing Zhai 1, Zijun Jia 1, Jianxin Chen 1, Yingwu Zhou 2,* and Wei Wang 1,* 1 Beijing University of Chinese Medicine, Bei San Huan East Road, Beijing 100029, China; [email protected] (K.G.); [email protected] (C.Z.); [email protected] (H.Z.); [email protected] (J.W.); [email protected] (Z.W.); [email protected] (X.Z.); [email protected] (Z.J.); [email protected] (J.C.) 2 Beijing Gulou Hospital of Traditional Chinese Medicine, 13 DouFuChi Hutong, Dongcheng District, Beijing 100009, China; [email protected] * Correspondence: [email protected] (Y.Z.); [email protected] (W.W.); Tel.: +86-10-6401-2858 (Y.Z.); +86-10-6428-7452 (W.W.) † These authors contributed equally to this work. Academic Editor: Derek J. McPhee Received: 13 October 2016; Accepted: 16 November 2016; Published: 23 November 2016 Abstract: 1-Deoxynojirimycin (DNJ, C6H13NO4, 163.17 g/mol), an alkaloid azasugar or iminosugar, is a biologically active natural compound that exists in mulberry leaves and Commelina communis (dayflower) as well as from several bacterial strains such as Bacillus and Streptomyces species. Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features. Therefore, the aim of this detailed review article is to summarize the existing knowledge on occurrence, extraction, purification, determination, chemistry, and bioactivities of DNJ, so that researchers may use it to explore future perspectives of research on DNJ. Moreover, possible molecular targets of DNJ will also be investigated using suitable in silico approach. Keywords: iminosugar; mulberry; Bacillus; fermentation; silkworms; antihyperglycemic; anti-obesity; antiviral; molecular targets 1. Introduction Polyhydroxylated piperidines and their derivatives are famous for their excellent bioactivities [1]. Iminosugars contain an analog of pyranose ring or D-glucose, in which the ring oxygen atom is replaced by a nitrogen atom. 1-Deoxyiminosugars are chemically more stable than normal iminosugars because of absence of a hydroxyl group at the C1 position. Among the iminosugars, naturally occurring 1-deoxyiminosugars such as DNJ are strong glycosidase inhibitors [2]. Originally, reduction of nojirimycin led to the chemical synthesis of DNJ [3]; afterward, DNJ was found from natural source, i.e., mulberry tree root and Bacillus species [4,5]. 1-Deoxynojirimycin (DNJ, C6H13NO4, 163.17 g/mol) (Figure1), an alkaloid azasugar or iminosugar, is a biologically active natural compound [6–8]. The IUPAC name of DNJ is (2R,3R,4R,5S)- 2-(hydroxymethyl)piperidine-3,4,5-triol. It is also known as moranoline [9]. Various derivatives of DNJ are N-azidopropyl-1-deoxynojirimycin, N-nonyl-1-deoxynojirimycin, 1-deoxynojirimycin-6- phosphate, and N-methyl-1-deoxynojiri-mycin-6-phosphate [8]. It exists in mulberry leaves and Commelina communis (dayflower) as well as from several bacterial strains such as Bacillus and Streptomyces species [7]. Molecules 2016, 21, 1600; doi:10.3390/molecules21111600 www.mdpi.com/journal/molecules Molecules 2016, 21, 1600 2 of 15 Molecules 2016, 21, 1600 2 of 14 Figure 1. Chemical structure of 1-Deoxynojirimycin [7]. Figure 1. Chemical structure of 1-Deoxynojirimycin [7]. AfterAfter extraction, extraction, DNJDNJ contents contents can can be determin be determineded by HPLC by using HPLC various using detectors various such detectors as suchfluorescent, as fluorescent, evaporative evaporative light-scattering light-scattering detector, pulsed detector,amperometric, pulsed and Mass amperometric, spectrometer [10–12]. and Mass spectrometerSince DNJ [ molecule10–12]. Since does not DNJ contain molecule chromophore, does not the contain quantification chromophore, of DNJ through the quantification spectral analysis of DNJ needs derivatization, i.e., an analytical approach for quantification of nitrogen-containing compounds through spectral analysis needs derivatization, i.e., an analytical approach for quantification of [13–16]. To quantify and resolve structural information of DNJ by GC-MS, Bajpai and Rao used nitrogen-containing compounds [13–16]. To quantify and resolve structural information of DNJ trimethylsilyl (TMS) derivatization [7]. by GC-MS,The Bajpai pharmacokinetic and Rao used of DNJ trimethylsilyl after oral administrati (TMS)on derivatization has been studies [7]. by some researchers [17–19]. TheMoreover pharmacokinetic, DNJ has many of biological DNJ after activities, oral administration including antihyperglycemic has been studies [20–25], by some anti-obesity researchers [26–30],[17 –19]. Moreover,and anti-viral DNJ has [31] many have biological also been activities,reported [32–35]. including antihyperglycemic [20–25], anti-obesity [26–30], and anti-viralCurrently, [31] havethe prediction also been of biological reported targets [32–35 of]. small drug molecules has become very easy owing Currently,to the rapid the growth prediction of bioactivity of biological databases, targets in silico of small target drug fishing molecules approaches has become and accessible very easy web owing to theservices rapid [36]. growth There of are bioactivity many approaches databases, to in in silico silico target target fishing fishing including approaches the structure-based and accessible and web servicesthe ligand-based [36]. There aremethods, many data approaches mining, and to inchemical silico targetsimilarity fishing searching including [37]. Then, the structure-based the output data and of these approaches are validated by adopting useful modality. The structure-based target prediction the ligand-based methods, data mining, and chemical similarity searching [37]. Then, the output data methods are appropriate to the drug-like small organic entities, which induce biological effects but of these approaches are validated by adopting useful modality. The structure-based target prediction have ambiguous macromolecular targets [36]. methodsTherefore, are appropriate the aim to of the this drug-like detailed review small organicarticle is entities,to summarize which the induce existing biological knowledge effects on but haveoccurrence, ambiguous extraction, macromolecular purification, targets determination, [36]. chemistry, and bioactivities of DNJ, so that the Therefore,researchers may the use aim it ofto explore this detailed future perspectives review article of research is tosummarize on DNJ. Moreover, the existing possibleknowledge molecular on occurrence,targets of extraction, DNJ will also purification, be investigated determination, using suitable chemistry, in silico approach. and bioactivities of DNJ, so that the researchers may use it to explore future perspectives of research on DNJ. Moreover, possible molecular targets2. 1-Deoxynojirimycin of DNJ will also be investigated using suitable in silico approach. 2. 1-Deoxynojirimycin2.1. Occurrence 1-Deoxynojirimycin (DNJ), a product of fermentation, exists in mulberry leaves and 2.1. OccurrenceCommelina communis (dayflower) as well as is isolated from several bacterial strains such as Bacillus and Streptomyces species [7,8]. Mulberry, a common deciduous plant, belongs to the genus Morus (Moraceae 1-Deoxynojirimycin (DNJ), a product of fermentation, exists in mulberry leaves and family). The botanical and pharmaceutical names of mulberry tree are Morus alba L. and Folium mori, Commelina communis (dayflower) as well as is isolated from several bacterial strains such as Bacillus respectively [38]. Mulberry tree is found in countries with a subtropical or mild temperate environment, and Streptomycesincluding China,species Japan, [ 7Korea,,8]. Mulberry, India, Pakistan, a common and other deciduous Asian countries plant, [39]. belongs By reason to the of genus folkloreMorus (Moraceaetonic, mulberry family). leaves The botanical have been and used pharmaceutical as an anti-diabetic names tea. The of mulberrygeneral use tree of mulberry are Morus includes alba L. and Foliumsilkworm mori, respectively (Bombyx mori [ 38L.)]. feeding Mulberry (Figures tree 2 isand found 3) [40], in fruit countries production with [41], a subtropical and medicine or preparation mild temperate environment,[42,43]. Mulberry including leaves China, are used Japan, as Korea,a source India, of protein Pakistan, in food and products other Asian[44]. Many countries scientific [39 studies]. By reason of folklorehave reported tonic, mulberry the medicinal leaves importance have been of usedmulberry as an [45]. anti-diabetic Mulberry leaves tea. The are traditionally general use used of mulberry as includesmedicine silkworm for controlling (Bombyx blood mori L.) sugar feeding level [20,46–48]. (Figures2 andStudies3)[ have40], also fruit reported production the effectiveness [41], and medicine of preparationmulberry [ 42leaves,43]. in Mulberry skin aging leaves[49,50] and are neurodegenerative used as a source disorders of protein including in food Alzheimer’s products disease [44]. Many and Parkinson’s disease [51]. Moreover, sedative effect of mulberry fruits and anti-inflammatory, scientific studies have reported the medicinal importance of mulberry [45]. Mulberry leaves are diuretic, antitussive, and antipyretic properties of mulberry root bark have been studies [52]. In addition traditionally used as medicine for controlling blood sugar level [20,46–48]. Studies have also reported to DNJ, many other
Recommended publications
  • Enzymatic Encoding Methods for Efficient Synthesis Of
    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
    [Show full text]
  • Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected]
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School July 2017 Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected] Follow this and additional works at: http://scholarcommons.usf.edu/etd Part of the Pathology Commons Scholar Commons Citation Mohamed, Mai, "Role of Amylase in Ovarian Cancer" (2017). Graduate Theses and Dissertations. http://scholarcommons.usf.edu/etd/6907 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Role of Amylase in Ovarian Cancer by Mai Mohamed A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Pathology and Cell Biology Morsani College of Medicine University of South Florida Major Professor: Patricia Kruk, Ph.D. Paula C. Bickford, Ph.D. Meera Nanjundan, Ph.D. Marzenna Wiranowska, Ph.D. Lauri Wright, Ph.D. Date of Approval: June 29, 2017 Keywords: ovarian cancer, amylase, computational analyses, glycocalyx, cellular invasion Copyright © 2017, Mai Mohamed Dedication This dissertation is dedicated to my parents, Ahmed and Fatma, who have always stressed the importance of education, and, throughout my education, have been my strongest source of encouragement and support. They always believed in me and I am eternally grateful to them. I would also like to thank my brothers, Mohamed and Hussien, and my sister, Mariam. I would also like to thank my husband, Ahmed.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,689,046 B2 Mayall Et Al
    USOO9689046B2 (12) United States Patent (10) Patent No.: US 9,689,046 B2 Mayall et al. (45) Date of Patent: Jun. 27, 2017 (54) SYSTEM AND METHODS FOR THE FOREIGN PATENT DOCUMENTS DETECTION OF MULTIPLE CHEMICAL WO O125472 A1 4/2001 COMPOUNDS WO O169245 A2 9, 2001 (71) Applicants: Robert Matthew Mayall, Calgary (CA); Emily Candice Hicks, Calgary OTHER PUBLICATIONS (CA); Margaret Mary-Flora Bebeselea, A. et al., “Electrochemical Degradation and Determina Renaud-Young, Calgary (CA); David tion of 4-Nitrophenol Using Multiple Pulsed Amperometry at Christopher Lloyd, Calgary (CA); Lisa Graphite Based Electrodes', Chem. Bull. “Politehnica” Univ. Kara Oberding, Calgary (CA); Iain (Timisoara), vol. 53(67), 1-2, 2008. Fraser Scotney George, Calgary (CA) Ben-Yoav. H. et al., “A whole cell electrochemical biosensor for water genotoxicity bio-detection”. Electrochimica Acta, 2009, 54(25), 6113-6118. (72) Inventors: Robert Matthew Mayall, Calgary Biran, I. et al., “On-line monitoring of gene expression'. Microbi (CA); Emily Candice Hicks, Calgary ology (Reading, England), 1999, 145 (Pt 8), 2129-2133. (CA); Margaret Mary-Flora Da Silva, P.S. et al., “Electrochemical Behavior of Hydroquinone Renaud-Young, Calgary (CA); David and Catechol at a Silsesquioxane-Modified Carbon Paste Elec trode'. J. Braz. Chem. Soc., vol. 24, No. 4, 695-699, 2013. Christopher Lloyd, Calgary (CA); Lisa Enache, T. A. & Oliveira-Brett, A. M., "Phenol and Para-Substituted Kara Oberding, Calgary (CA); Iain Phenols Electrochemical Oxidation Pathways”, Journal of Fraser Scotney George, Calgary (CA) Electroanalytical Chemistry, 2011, 1-35. Etesami, M. et al., “Electrooxidation of hydroquinone on simply prepared Au-Pt bimetallic nanoparticles'. Science China, Chem (73) Assignee: FREDSENSE TECHNOLOGIES istry, vol.
    [Show full text]
  • The Design, Synthesis and Enzymatic Evaluation of Aminocyclitol Inhibitors of Glucocerebrosidase
    Lakehead University Knowledge Commons,http://knowledgecommons.lakeheadu.ca Electronic Theses and Dissertations Electronic Theses and Dissertations from 2009 2014-01-22 The design, synthesis and enzymatic evaluation of aminocyclitol inhibitors of glucocerebrosidase Adams, Benjamin Tyler http://knowledgecommons.lakeheadu.ca/handle/2453/478 Downloaded from Lakehead University, KnowledgeCommons THE DESIGN, SYNTHESIS AND ENZYMATIC EVALUATION OF AMINOCYCLITOL INHIBITORS OF GLUCOCEREBROSIDASE By Benjamin Tyler Adams A Thesis submitted to The Department of Chemistry Faculty of Science and Environmental Studies Lakehead University In partial fulfillment of the requirements for the degree of Master of Science August 2013 © Benjamin Tyler Adams, 2013 i Abstract Gaucher disease, the most common lysosomal storage disorder, is caused by mutations in the GBA gene which codes for the enzyme glucocerebrosidase (GCase) resulting in its deficiency. GCase deficiency results in the accumulation of its substrate glucosylceramide (GlcCer) within the lysosomes leading to various severities of hepatosplenomegaly, bone disease and neurodegeneration. For most forms of Gaucher disease, the mutations in the GBA gene cause the enzyme to misfold but retain catalytic activity. However, the misfolded mutant enzyme is recognized and degraded by the endoplasmic reticulum-associated degradation (ERAD) pathway prior to delivery into the lysosome. Symptoms begin to show in patients when the function of the defective enzyme drops below 10-20% residual enzyme activity. There are currently three therapeutic approaches to treat Gaucher disease: enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and a relatively recent addition, enzyme enhancement therapy (EET) through the use of pharmacological chaperones. Many pharmacological chaperones are competitive inhibitors that are capable of enhancing lysosomal GCase activity by stabilizing the folded conformation of GCase enabling it to bypass the ERAD pathway.
    [Show full text]
  • LCT Gene Lactase
    LCT gene lactase Normal Function The LCT gene provides instructions for making an enzyme called lactase. This enzyme helps to digest lactose, a sugar found in milk and other dairy products. Lactase is produced by cells that line the walls of the small intestine. These cells, called intestinal epithelial cells, have finger-like projections called microvilli that absorb nutrients from food as it passes through the intestine so they can be absorbed into the bloodstream. Based on their appearance, groups of these microvilli are known collectively as the brush border. Lactase functions at the brush border to break down lactose into smaller sugars called glucose and galactose for absorption. Health Conditions Related to Genetic Changes Lactose intolerance At least nine LCT gene mutations cause congenital lactase deficiency, also called congenital alactasia. In this disorder, infants are unable to break down lactose (lactose intolerance) in breast milk or formula. The LCT gene mutations change single protein building blocks (amino acids) in the lactase enzyme or result in an enzyme that is abnormally short. The mutations are believed to interfere with the function of the lactase enzyme, leading to undigested lactose in the small intestine and causing severe diarrhea. Lactose intolerance in adulthood is caused by gradually decreasing activity (expression) of the LCT gene after infancy, which occurs in most humans. Other Names for This Gene • LAC • lactase-glycosylceramidase • lactase-phlorizin hydrolase • lactase-phlorizin hydrolase preproprotein
    [Show full text]
  • Glucocerebrosidase: Functions in and Beyond the Lysosome
    Journal of Clinical Medicine Review Glucocerebrosidase: Functions in and Beyond the Lysosome Daphne E.C. Boer 1, Jeroen van Smeden 2,3, Joke A. Bouwstra 2 and Johannes M.F.G Aerts 1,* 1 Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, Faculty of Science, 2333 CC Leiden, The Netherlands; [email protected] 2 Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Faculty of Science, 2333 CC Leiden, The Netherlands; [email protected] (J.v.S.); [email protected] (J.A.B.) 3 Centre for Human Drug Research, 2333 CL Leiden, The Netherlands * Correspondence: [email protected] Received: 29 January 2020; Accepted: 4 March 2020; Published: 9 March 2020 Abstract: Glucocerebrosidase (GCase) is a retaining β-glucosidase with acid pH optimum metabolizing the glycosphingolipid glucosylceramide (GlcCer) to ceramide and glucose. Inherited deficiency of GCase causes the lysosomal storage disorder named Gaucher disease (GD). In GCase-deficient GD patients the accumulation of GlcCer in lysosomes of tissue macrophages is prominent. Based on the above, the key function of GCase as lysosomal hydrolase is well recognized, however it has become apparent that GCase fulfills in the human body at least one other key function beyond lysosomes. Crucially, GCase generates ceramides from GlcCer molecules in the outer part of the skin, a process essential for optimal skin barrier property and survival. This review covers the functions of GCase in and beyond lysosomes and also pays attention to the increasing insight in hitherto unexpected catalytic versatility of the enzyme. Keywords: glucocerebrosidase; lysosome; glucosylceramide; skin; Gaucher disease 1.
    [Show full text]
  • Impact of Gba2 on Neuronopathic Gaucher's
    Nakanishi et al. Mol Brain (2021) 14:80 https://doi.org/10.1186/s13041-021-00790-x RESEARCH Open Access Impact of Gba2 on neuronopathic Gaucher’s disease and α-synuclein accumulation in medaka (Oryzias latipes) Etsuro Nakanishi1, Norihito Uemura1,6* , Hisako Akiyama2, Masato Kinoshita3, Sawamura Masanori1, Yosuke Taruno1, Hodaka Yamakado1, Shu‑ichi Matsuzawa1, Shunichi Takeda4, Yoshio Hirabayashi5 and Ryosuke Takahashi1* Abstract Homozygous mutations in the lysosomal glucocerebrosidase gene, GBA1, cause Gaucher’s disease (GD), while heterozygous mutations in GBA1 are a strong risk factor for Parkinson’s disease (PD), whose pathological hallmark is intraneuronal α‑synuclein (asyn) aggregates. We previously reported that gba1 knockout (KO) medaka exhibited glucosylceramide accumulation and neuronopathic GD phenotypes, including short lifespan, the dopaminergic and noradrenergic neuronal cell loss, microglial activation, and swimming abnormality, with asyn accumulation in the brains. A recent study reported that deletion of GBA2, non‑lysosomal glucocerebrosidase, in a non‑neuronopathic GD mouse model rescued its phenotypes. In the present study, we generated gba2 KO medaka and examined the efect of Gba2 deletion on the phenotypes of gba1 KO medaka. The Gba2 deletion in gba1 KO medaka resulted in the exacerbation of glucosylceramide accumulation and no improvement in neuronopathic GD pathological changes, asyn accumulation, or swimming abnormalities. Meanwhile, though gba2 KO medaka did not show any apparent phenotypes, biochemical analysis revealed asyn accumulation in the brains. gba2 KO medaka showed a trend towards an increase in sphingolipids in the brains, which is one of the possible causes of asyn accumulation. In conclusion, this study demonstrated that the deletion of Gba2 does not rescue the pathological changes or behavioral abnormalities of gba1 KO medaka, and GBA2 represents a novel factor afecting asyn accumulation in the brains.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • Amfep Guidance on REACH Pre-Registration of Enzymes
    Amfep/08/44 30 May 2008 Amfep guidance on REACH pre-registration of enzymes 1. Purpose and timing During the period 1 June to 1 December 2008, European enzyme manufacturers and importers can pre-register the enzyme substances currently manufactured in EU and imported into the EU for technical applications. Manufacturers and importers inside the EU may appoint Third Party Representatives to remain anonymous and if based outside the EU, they may appoint Only Representatives. The pre-registration provision of REACH enables substances to remain on the market subject to later registration in 2010, 2013 or 2018, depending on tonnage. Pre-registration is made to the European Chemicals Agency (ECHA) and result in the formation of a Substance Information Exchange Forum (SIEF) per enzyme. ECHA will publish a list of pre- registered substances by 1 January 2009. Amfep has formed a pre-consortium of members and associated manufacturing companies to prepare enzyme (pre-) registrations and SIEF discussions. The Amfep secretariat can be contacted for further information and on questions related to enzyme pre-registrations. This document is intended to facilitate pre-registration of enzymes. References are given to detailed guidance on enzyme identification, pre-registration and other REACH requirements. However, it must be considered as guidance only. Each potential registrant remains fully responsible for selecting its enzymes and making individual pre-registrations. 2. Scope Enzymes listed on the European chemicals inventory EINECS are considered phase-in (‘existing’) substances and can be pre-registered. Enzymes manufactured in the EU at least once after 31 May 1992, without being placed on the EU market by the manufacturer or importer, are regarded as phase-in substances.
    [Show full text]
  • Plant Glycosides and Glycosidases: a Treasure-Trove for Therapeutics
    fpls-11-00357 April 6, 2020 Time: 8:34 # 1 REVIEW published: 07 April 2020 doi: 10.3389/fpls.2020.00357 Plant Glycosides and Glycosidases: A Treasure-Trove for Therapeutics Kassiani Kytidou1*, Marta Artola1,2, Herman S. Overkleeft2 and Johannes M. F. G. Aerts1* 1 Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands, 2 Department of Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands Plants contain numerous glycoconjugates that are metabolized by specific glucosyltransferases and hydrolyzed by specific glycosidases, some also catalyzing synthetic transglycosylation reactions. The documented value of plant-derived glycoconjugates to beneficially modulate metabolism is first addressed. Next, focus is given to glycosidases, the central theme of the review. The therapeutic value of plant glycosidases is discussed as well as the present production in plant platforms of therapeutic human glycosidases used in enzyme replacement therapies. The increasing Edited by: knowledge on glycosidases, including structure and catalytic mechanism, is described. Aleš Svatoš, The novel insights have allowed the design of functionalized highly specific suicide Max Planck Institute for Chemical Ecology, Germany inhibitors of glycosidases. These so-called activity-based probes allow unprecedented Reviewed by: visualization of glycosidases cross-species. Here, special attention is paid on the use José Manuel García Fernández, of such probes in plant science that promote the discovery of novel enzymes and the Spanish National Research Council, Spain identification of potential therapeutic inhibitors and chaperones. Goro Taguchi, Keywords: plant glycosides, carbohydrate processing enzymes, glycosidases, glycosylation, enzyme Shinshu University, Japan replacement therapy (ERT), plant production platforms, glycosphingolipids, glycosidase activity-based probes *Correspondence: Kassiani Kytidou [email protected] INTRODUCTION Johannes M.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur Et Al
    US 20150240226A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur et al. (43) Pub. Date: Aug. 27, 2015 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/16 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/02 (2006.01) CI2N 9/78 (2006.01) (71) Applicant: BP Corporation North America Inc., CI2N 9/12 (2006.01) Naperville, IL (US) CI2N 9/24 (2006.01) CI2O 1/02 (2006.01) (72) Inventors: Eric J. Mathur, San Diego, CA (US); CI2N 9/42 (2006.01) Cathy Chang, San Marcos, CA (US) (52) U.S. Cl. CPC. CI2N 9/88 (2013.01); C12O 1/02 (2013.01); (21) Appl. No.: 14/630,006 CI2O I/04 (2013.01): CI2N 9/80 (2013.01); CI2N 9/241.1 (2013.01); C12N 9/0065 (22) Filed: Feb. 24, 2015 (2013.01); C12N 9/2437 (2013.01); C12N 9/14 Related U.S. Application Data (2013.01); C12N 9/16 (2013.01); C12N 9/0061 (2013.01); C12N 9/78 (2013.01); C12N 9/0071 (62) Division of application No. 13/400,365, filed on Feb. (2013.01); C12N 9/1241 (2013.01): CI2N 20, 2012, now Pat. No. 8,962,800, which is a division 9/2482 (2013.01); C07K 2/00 (2013.01); C12Y of application No. 1 1/817,403, filed on May 7, 2008, 305/01004 (2013.01); C12Y 1 1 1/01016 now Pat. No. 8,119,385, filed as application No. PCT/ (2013.01); C12Y302/01004 (2013.01); C12Y US2006/007642 on Mar. 3, 2006.
    [Show full text]
  • Klotho Structure-Function Relationships in Breast Cancer Tumor Suppressor
    Author Manuscript Published OnlineFirst on June 25, 2015; DOI: 10.1158/1541-7786.MCR-15-0141 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Klotho structure-function relationships in breast cancer Tumor Suppressor Activity of Klotho in Breast Cancer is Revealed by Structure-function Analysis Hagai Ligumsky1, 2#, Tami Rubinek1, Keren Merenbakh-Lamin1, 2, Adva Yeheskel3, Rotem Sertchook4, Shiri Shahmoon1, 2, Sarit Aviel-Ronen5 and Ido Wolf1, 2 1 The Oncology Division, Tel Aviv Sourasky Medical Center, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3Bioinformatics Unit, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel; 4Bioinformatics and Biologial Computing Unit, Weizmann Institute of Science, Rehovot, Israel. 5Department of Pathology, Chaim Sheba Medical Center, Ramat Gan, Israel. Running title: Klotho structure-function relationships in breast cancer To whom correspondence should be addressed: Ido Wolf, Oncology Division, Tel Aviv Sourasky Medical Center, 64239, Tel Aviv, Israel. Phone: 972-52-736-0558 FAX : 972-3- 697-3030. E-mail: [email protected] # This work was performed in partial fulfillment of the requirements for a Ph.D. degree. Key words: klotho, breast cancer, KL1, KL2, glucuronidase Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed. 1 Downloaded from mcr.aacrjournals.org on September 27, 2021. © 2015 American Association for Cancer Research. Author Manuscript Published OnlineFirst on June 25, 2015; DOI: 10.1158/1541-7786.MCR-15-0141 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]